Question 1

What is PT-00114?

Accepted Answer

PT-00114 is a Other.

Question 2

How often does PT-00114 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was PT-00114 first tracked by Ergen?

Accepted Answer

First tracked on May 19, 2026.

Question 4

When was PT-00114 last mentioned in news?

Accepted Answer

Last active on May 19, 2026.

Question 5

What is PT-00114's current news sentiment?

Accepted Answer

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is PT-00114 in global news coverage?

Accepted Answer

Attention score of 3, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving PT-00114?

Accepted Answer

Protagenic Therapeutics Engages Regulatory, Operations Advisors (May 19, 2026, 6 articles).

Question 8

How did the "Protagenic Therapeutics Engages Regulatory, Operations Advisors" event impact PT-00114?

Accepted Answer

PT-00114 is AnBogen Therapeutics' lead clinical asset, a neuropeptide targeting stress-related neuropsychiatric disorders, which is being advanced into Phase 2 clinical studies with the support of the new engagements.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.